Search is Powered by Google
Cancer / Oncology News

Potential Pharmaceutical Royalties To Be Donated To Madagascar

Main Category: Cancer / Oncology
Also Included In: Biology / Biochemistry;  Water - Air Quality / Agriculture;  Tropical Diseases
Article Date: 13 Nov 2008 - 1:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The National Institutes of Health has renewed a five-year research grant for a total of $2.5 million to an international biodiversity group lead by David G.I. Kingston, University Distinguished Professor of Chemistry at Virginia Tech.

Kingston is known internationally for his work in biodiversity and development of naturally occurring cancer-fighting agents. Consistent with the Convention on Biological Diversity, he will share a portion of any royalties generated by sales of pharmaceuticals developed from this work with Madagascar, the country in which the research is taking place.

The award is the third competitive renewal of a research program that Kingston began in 1993. The grant was accompanied by a companion award for the United States Department of Agriculture of $1.25 million over the next five years.

The overall goals of the International Cooperative Biodiversity Group are to foster biodiversity conservation, economic development, and drug discovery in Madagascar. The proposed research integrates the work of eight different research groups, located in the United States and around the world.

Kingston will lead a group at Virginia Tech that will focus on biodiversity in the areas of cancer and malaria. Other research groups will focus on immunology, neurological disease, and agrochemistry. Madagascar is home to 5 percent of the world's plant and animal species, of which more than 80 percent are endemic to the region. This makes it a rich source of material for the team to screen for compounds with natural product activity of possible interest and value.

"The first naturally occurring anticancer drugs were isolated from the Madagascar periwinkle," Kingston said. "It is our hope that we can find new anticancer agents from the country's plants, microbes, or marine organisms so that we can provide a benefit to cancer patients as well as reward Madagascar for preserving its biodiversity."

The group will also carry out economic development and biodiversity conservation initiatives in Madagascar Economic development work will make use of funds donated by industrial partners, while biodiversity conservation initiatives will include the completion of biodiversity surveys of well-defined forest preserves and training in botanical methods.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Source: Catherine Doss
Virginia Tech




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...